Patents by Inventor Harvey Bumpers

Harvey Bumpers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumor cytotoxicity induced by modulators of the CXCR4 receptor
    Patent number: 7960346
    Abstract: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: June 14, 2011
    Assignee: Morehouse School of Medicine
    Inventors: Vincent C. Bond, James W. Lillard, Ming Bo Huang, Harvey Bumpers, Michael Powell
  • Tumor cytotoxicity induced by modulators of the CXCR4 receptor
    Publication number: 20080227720
    Abstract: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.
    Type: Application
    Filed: November 5, 2007
    Publication date: September 18, 2008
    Inventors: Vincent C. Bond, James W. Lillard, Ming Bo Huang, Harvey Bumpers, Michael Powell
  • Tumor cytotoxicity induced by modulators of the CXCR4 receptor
    Patent number: 7312305
    Abstract: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.
    Type: Grant
    Filed: March 20, 2003
    Date of Patent: December 25, 2007
    Assignee: Morehouse School of Medicine
    Inventors: Vincent C. Bond, James Lillard, Ming Bo Huang, Harvey Bumpers, Michael Powell
  • Tumor cytotoxicity induced by modulators of the CXCR4 receptor
    Publication number: 20040037825
    Abstract: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.
    Type: Application
    Filed: March 20, 2003
    Publication date: February 26, 2004
    Inventors: Vincent C. Bond, James W. Lillard, Ming Bo Huang, Harvey Bumpers, Michael Powell